Nguyen, Tuong Vi

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 101

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Lonial, S., van de Donk, N. W. C. J., Popat, R., Zonder, J. A., Minnema, M. C., Larsen, J., Nguyen, T. V., Chen, M. S., Bensmaine, A., Cota, M., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 49